Literature DB >> 28605595

Efficient Codelivery of Paclitaxel and Curcumin by Novel Bottlebrush Copolymer-based Micelles.

Qing Yao1,2, David C Gutierrez3, Ngoc Ha Hoang1,4,5, Dongin Kim1, Ruoning Wang6, Christopher Hobbs3, Lin Zhu1.   

Abstract

The novel self-assembling bottlebrush polyethylene glycol-polynorbornene-thiocresol block copolymers (PEG-PNB-TC) were synthesized by the ring opening metathesis polymerization (ROMP), followed by functionalization of the polymer backbone via the thio-bromo "click" postpolymerization strategy. The PEG-PNB-TC copolymers could easily self-assemble into the nanoscale core-shell polymeric micelles. The hydrophobic anticancer drugs, such as paclitaxel (PTX), could be loaded into their hydrophobic core to form a stable drug-loaded micelle with a superior drug loading capacity of up to ∼35% (w/w). The sustained drug release behavior of the PEG-PNB-TC micelles was observed under a simulated "sink condition". Compared with commercial PTX formulation (Taxol), the PTX-loaded PEG-PNB-TC micelles showed the enhanced in vitro cellular uptake and comparable cytotoxicity in the drug-sensitive cancer cells, while the copolymers were much safer than Cremophor EL, the surfactant used in Taxol. Furthermore, curcumin (CUR), a natural chemotherapy drug sensitizer, was successfully coloaded with PTX into the PEG-PNB-TC micelles. High drug loading capacity of the PEG-PNB-TC micelles allowed for easy adjustment of drug doses and the ratio of the coloaded drugs. The combination of PTX and CUR showed synergistic anticancer effect in both the drug mixture and drug coloaded micelles at high CUR/PTX ratio, while low CRU/PTX ratio only exhibited additive effects. The combinatorial effects remarkably circumvented the PTX resistance in the multidrug resistant (MDR) cancer cells. Due to the easy polymerization and functionalization, excellent self-assembly capability, high drug loading capability, and great stability, the PEG-PNB-TC copolymers might be a promising nanomaterial for delivery of the hydrophobic anticancer drugs, especially for combination drug therapy.

Entities:  

Keywords:  combination drug therapy; drug delivery; drug resistance; polymeric micelles; polynorbornene copolymer

Mesh:

Substances:

Year:  2017        PMID: 28605595     DOI: 10.1021/acs.molpharmaceut.7b00278

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  14 in total

1.  pH-triggered surface charge-switchable polymer micelles for the co-delivery of paclitaxel/disulfiram and overcoming multidrug resistance in cancer.

Authors:  Qiang Huo; Jianhua Zhu; Yimin Niu; Huihui Shi; Yaxiang Gong; Yang Li; Huihui Song; Yang Liu
Journal:  Int J Nanomedicine       Date:  2017-12-04

2.  Arginine, glycine, aspartic acid peptide-modified paclitaxel and curcumin co-loaded liposome for the treatment of lung cancer: in vitro/vivo evaluation.

Authors:  Kanqiu Jiang; Mingjing Shen; Weihua Xu
Journal:  Int J Nanomedicine       Date:  2018-04-27

3.  Identification and validation of NOLC1 as a potential target for enhancing sensitivity in multidrug resistant non-small cell lung cancer cells.

Authors:  Huaping Huang; Tangying Li; Mingjing Chen; Feng Liu; Haifeng Wu; Jie Wang; Jialiang Chen; Xi Li
Journal:  Cell Mol Biol Lett       Date:  2018-11-27       Impact factor: 5.787

4.  OCTN2-targeted nanoparticles for oral delivery of paclitaxel: differential impact of the polyethylene glycol linker size on drug delivery in vitro, in situ, and in vivo.

Authors:  Longfa Kou; Rui Sun; Shuyi Xiao; Xiao Cui; Jin Sun; Vadivel Ganapathy; Qing Yao; Ruijie Chen
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

5.  In vitro and in vivo evaluation of didymin cyclodextrin inclusion complexes: characterization and chemosensitization activity.

Authors:  Qing Yao; Meng-Ting Lin; Qing-Hua Lan; Zhi-Wei Huang; Ya-Wen Zheng; Xue Jiang; Yin-Di Zhu; Longfa Kou; He-Lin Xu; Ying-Zheng Zhao
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

6.  Co-delivery of plantamajoside and sorafenib by a multi-functional nanoparticle to combat the drug resistance of hepatocellular carcinoma through reprograming the tumor hypoxic microenvironment.

Authors:  Ying Zan; Zhijun Dai; Liang Liang; Yujiao Deng; Lei Dong
Journal:  Drug Deliv       Date:  2019-12       Impact factor: 6.419

Review 7.  The Application of Nanotechnology in the Codelivery of Active Constituents of Plants and Chemotherapeutics for Overcoming Physiological Barriers during Antitumor Treatment.

Authors:  Qiushuang Li; Yang Xiong; Conghua Ji; Zhiqiang Yan
Journal:  Biomed Res Int       Date:  2019-12-13       Impact factor: 3.411

8.  Co-Delivery of Curcumin and Paclitaxel by "Core-Shell" Targeting Amphiphilic Copolymer to Reverse Resistance in the Treatment of Ovarian Cancer.

Authors:  Meng-Dan Zhao; Jun-Qin Li; Feng-Ying Chen; Wei Dong; Li-Juan Wen; Wei-Dong Fei; Xiao Zhang; Pei-Lei Yang; Xin-Mei Zhang; Cai-Hong Zheng
Journal:  Int J Nanomedicine       Date:  2019-12-02

9.  Dual Targeting EGFR and STAT3 With Erlotinib and Alantolactone Co-Loaded PLGA Nanoparticles for Pancreatic Cancer Treatment.

Authors:  Shihui Bao; Hailun Zheng; Jinyao Ye; Huirong Huang; Bin Zhou; Qing Yao; Guangyong Lin; Hailin Zhang; Longfa Kou; Ruijie Chen
Journal:  Front Pharmacol       Date:  2021-03-19       Impact factor: 5.810

10.  l-Carnitine conjugated chitosan-stearic acid polymeric micelles for improving the oral bioavailability of paclitaxel.

Authors:  Tan Yang; Jianfang Feng; Qian Zhang; Wei Wu; Hailan Mo; Lanzhen Huang; Wei Zhang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.